Sign In
Buy BVNKF
$27.69
+0 (+0%)
At Close: Jul 31, 2026
Bavarian Nordic seeks EU approval to extend mpox vaccine to adolescents
02:07am, Friday, 16'th Aug 2024
Danish biotech Bavarian Nordic said on Friday it had submitted data to the European Union's drug regulator for approval to extend the use of the company's mpox and smallpox vaccine to adolescents aged
Bavarian Nordic stock soars over 15% as WHO declares Mpox a global health emergency
01:18pm, Thursday, 15'th Aug 2024
Shares of Bavarian Nordic, a Danish vaccine manufacturer, surged over 15% on Thursday following the World Health Organization's (WHO) declaration of Mpox as a public health emergency. This announcem
Health stocks jump as WHO declares mpox global health emergency
11:26am, Thursday, 15'th Aug 2024
Shares of Danish vaccine maker Bavarian Nordic jumped as much as 17% Thursday amid a wider rally for associated healthcare stocks. It comes after the World Health Organization declared an escalating m
Bavarian Nordic to donate mpox vaccine doses following African emergency declaration
05:17pm, Tuesday, 13'th Aug 2024
Danish biotech firm Bavarian Nordic said on Tuesday it will donate 40,000 doses of its mpox vaccine to Africa's top public health body, after the body declared an emergency.
Bavarian Nordic Announces FDA Acceptance and Priority Review of the BLA for its Chikungunya Vaccine
01:44pm, Tuesday, 13'th Aug 2024
COPENHAGEN, Denmark, August 13, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the Biologics Lic
Bavarian Nordic Joins Global Efforts to Fight Mpox Outbreak in Africa
10:27am, Friday, 28'th Jun 2024
COPENHAGEN, Denmark, June 28, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced an extended commitment to help fight the current mpox outbreak in Africa. The Company's MVA-BN vaccine, the only
Bavarian Nordic Completes BLA Submission to U.S. FDA for its Chikungunya Vaccine Candidate
10:21am, Monday, 17'th Jun 2024
COPENHAGEN, Denmark, June 17, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced the completion of the rolling submission process which was initiated in April 2024 with the U.S. Food and Drug Ad
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program and Termination of Share Buy-Back Program
05:25pm, Tuesday, 21'st May 2024
COPENHAGEN, Denmark, May 21, 2024 – Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on May 8, 2024, has now been terminated, as the inten
EVP and Chief Medical Officer Laurence de Moerlooze Will Be Leaving Bavarian Nordic
08:00am, Tuesday, 21'st May 2024
COPENHAGEN, Denmark, May 21, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced that Laurence de Moerlooze will leave her position as Executive Vice President and Chief Medical Officer in the Co
Bavarian Nordic A/S (BVNKF) Q1 2024 Earnings Call Transcript
08:03am, Saturday, 11'th May 2024
Bavarian Nordic A/S (OTCPK:BVNKF) Q1 2024 Earnings Conference Call May 8, 2024 8:00 AM ET Company Participants Rolf Sorensen - VP, IR & Communications Paul Chaplin - President & CEO Henrik Juuel - EVP
Bavarian Nordic Receives 65 mEUR Contract to Supply Smallpox Vaccines for EU Strategic Reserve
03:30pm, Monday, 29'th Apr 2024
COPENHAGEN, Denmark, April 29, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced the award of a contract valued at EUR 65 million to supply its MVA-BN® smallpox vaccine to the strategic reserv
Bavarian Nordic Initiates Rolling Submission of Biologics License Application with FDA for its Chikungunya Vaccine Candidate
09:03am, Monday, 29'th Apr 2024
COPENHAGEN, Denmark, April 29, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced that it has initiated the rolling submission process with the U.S. Food and Drug Administration (FDA) for a Biol
COPENHAGEN, Denmark, April 22, 2024 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company's shares/related securities by persons holding ma
Resolutions of the Annual General Meeting 2024 of Bavarian Nordic A/S
12:20pm, Tuesday, 16'th Apr 2024
COPENHAGEN, Denmark, April 16, 2024 – Bavarian Nordic A/S (OMX: BAVA) today held the Annual General Meeting with the following results:
Bavarian Nordic Receives Approval of Smallpox and Mpox Vaccine in Switzerland
08:29am, Wednesday, 13'th Mar 2024
COPENHAGEN, Denmark, March 13, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Swiss Agency for Therapeutic Products, Swissmedic, has approved JYNNEOS® (MVA-BN) for active immunizat
